Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -129,335
▼ 23% vs 2024
Profit
Caution€ -1.5 million
▼ 49% vs 2024
Debts
Low€ 1.7 million
▲ 15% vs 2024
SIMABS from Diepenbeek, company number BE0732709096, closed financial year 2025 with a result of € -1.5 million after tax. For that financial year SIMABS recorded a gross margin of € -129,335 and equity of € 1 million. Compared with financial year 2024, the result moved from € -986,869 to € -1.5 million. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
What happened at SIMABS?
What happened at SIMABS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1.5 million. Source: NBB ↗
- Chemsciences Middle East Fzc became a director. NBB
- Pilot Biologix BV BV became a director. NBB
- QbD Growth BV BV became a director. NBB
- Amber Vandecruys became a director. NBB
- Oak Projects BV BV stepped down as director. NBB
- Metatron Holding NV NV became a director. NBB
- Metatron Holding NV NV stepped down as director. NBB
In short
From € 370,847 loss in 2021 to € 1.5 million loss in 2025.
Paid € 4,409 in corporate taxes since 2021.
A new publication or filing at SIMABS? We notify you, reason included.
Follow SIMABSNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Behind SIMABS are Chemsciences Middle East Fzc, Pilot Biologix BV BV, QbD Growth BV BV, Eye-Tec BV BV and Amber Vandecruys. The same people are also behind QbD RepS, QbD Clinical Holding, QbD Clinical and TURNSTONE COMMUNICATIONS.
Directors
According to the 2025 annual accounts
Director · represented by Amit Tibrewala
since 2025
Director · represented by Koen Dierckx
since 2025
Director · represented by Bart Van Acker
Also active at: QbD RepS, QbD Clinical Holding, QbD Clinical +1 more
since 2025
Director · represented by Bram Keymolen
since 2023
Amber Vandecruys
Director
since 2025
Director · represented by Joachim Vandeput
since 2023 · until 2025
Director · represented by Jo Nelissen
Also active at: Poels, ABN KLIMATISATIE, ABN Cleanroom Technology +4 more
since 2025 · until 2025
Director · represented by Bart Van Acker
Also active at: Qarad EC-REP, QARAD, QbD Wallonia +5 more
since 2023 · until 2025
Nicolas Vandermarliere
Director
since 2023 · until 2025
Establishments
Establishment units
Physical locations of this company
Agoralaan Abis
3590 Diepenbeek
Wetenschapspark 9
3590 Diepenbeek
Active since 25 September 2025
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 14 companies are registered at this address.
Clinitude
€ 419,430 gross margin · 2025
FOx Biosystems
€ -763,895 gross margin · 2023
Highstar Engineering
€ -41,079 gross margin · 2024
IDEA FAMILY
€ -3,258 gross margin · 2025
BIOKEY
€ -25,987 gross margin · 2025
+9 more
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
COMBELL-AS, BE
Domain
Domain
simabs.com
Registered
2018-12-29
Registrar
Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA
Expires
2026-12-29
Website info
Features
Security
Network
Details
- Company number
- 0732.709.096
- VAT number
- BE 0732.709.096
- Registered office
- Agoralaan Abis, 3590 Diepenbeek
- Names & denominations
- SIMABS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 20 August 2019
- Peppol
- Active · Active since 25 Nov 2025
- Contact
- simabs.com info@simabs.com
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Vervaardiging van geneesmiddelen
Vervaardiging van overige farmaceutische producten
Vervaardiging van farmaceutische grondstoffen